Vyvgart Hytrulo (gMG) – Compliance Alert

Caution

This ad has patterns previously flagged by FDA.

Analysis of this 60s ad identified 2 enforcement patterns, primarily Fair Balance. Patterns span Visual Distraction, Fair Balance — “Family & Social Scenes” identified at 39.9s, previously cited in Jardiance (x3), Contrave, Qulipta. FDA enforcement letter on file dated Jan 30, 2026.

Recommended action: Escalate to regulatory affairs: FDA enforcement letter on file (Jan 30, 2026). Verify remediation status in PromoMats and confirm all content modifications address cited violations before next distribution.

Video Timeline

Risk disclosure: 28.0s – 46.8s (18.8s of 60.0s total — 31.3% of ad)

Risk Window

0s15s30s45s60s

Family & Social?Risk Window?

Patterns Detected (2)

Each pattern below is a known FDA enforcement concern, identified by matching this ad against 14 violation types from 34 FDA warning letters

Pattern	Dimension	Score	Evidence	CFR
Family & Social Scenes Warm family scenes that emotionally minimize risk information	Visual Distraction	79	1 clip	21 CFR 202.1(e)(1)	▶
FDA Concern: Risk information must be presented in a clear, conspicuous, and neutral manner without distracting visuals Previously cited: Jardiance (x3), Contrave, Qulipta, Calquence, Austedo (x2)
Benefit vs. Risk Time Imbalance Significantly more time spent on benefits than on risks	Fair Balance	63	1 metric	21 CFR 202.1(e)(3)(iii)	▶
FDA Concern: Risk and benefit information must be presented with equal prominence Previously cited: FABHALTA, Vyvgart Hytrulo (x2), Wegovy, Vonjo Benefit:Risk Ratio: 2.20:1

Compliance Alert: Vyvgart Hytrulo (gMG)

Recommendations